Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

Clin Cancer Res (2008) 14 (20): 6704–6711.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
From Natural Sources to Synthetic Derivatives: The Allyl Motif as a Powerful Tool for Fragment-Based Design in Cancer Treatment
  • Nora Astrain-Redin
  • Carmen Sanmartin
  • Arun K. Sharma
  • Daniel Plano
Journal of Medicinal Chemistry (2023) 66 (6): 3703.
Multivariate response regression with low-rank and generalized sparsity
  • Youngjin Cho
  • Seyoung Park
Journal of the Korean Statistical Society (2022) 51 (3): 847.
Chaperone-assisted E3 ligase CHIP: A double agent in cancer
  • Sunny Kumar
  • Malini Basu
  • Mrinal K. Ghosh
Genes & Diseases (2022) 9 (6): 1521.
HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)
  • Zi-Nan Li
  • Ying Luo
Oncology Reports (2022) 49 (1)
Combination therapies with HSP90 inhibitors against colorectal cancer
  • Kushtrim Kryeziu
  • Jarle Bruun
  • Tormod K. Guren
  • Anita Sveen
  • Ragnhild A. Lothe
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) 1871 (2): 240.
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression
  • Shima Zeynali-Moghaddam
  • Mahshid Mohammadian
  • Fatemeh Kheradmand
  • Anahita Fathi-Azarbayjani
  • Yousef Rasmi
  • Omid Esna-Ashari
  • Hassan Malekinejad
Gene (2019) 684: 30.
Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
  • Sangkyu Park
  • Jeong-A Park
  • Jae-Hyung Jeon
  • Younghee Lee
Biomolecules & Therapeutics (2019) 27 (5): 423.
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
  • Alexandra Canonici
  • Zulfiqar Qadir
  • Neil T. Conlon
  • Denis M. Collins
  • Neil A. O’Brien
  • Naomi Walsh
  • Alex J. Eustace
  • Norma O’Donovan
  • John Crown
Investigational New Drugs (2018) 36 (4): 581.
Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension
  • Guo-Kun Wang
  • Song-Hua Li
  • Zhi-Min Zhao
  • Su-Xuan Liu
  • Guan-Xin Zhang
  • Fan Yang
  • Yang Wang
  • Feng Wu
  • Xian-Xian Zhao
  • Zhi-Yun Xu
Oncotarget (2016) 7 (34): 54263.
Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells
  • Bin Wang
  • Linfeng Chen
  • Zhenhong Ni
  • Xufang Dai
  • Liyan Qin
  • Yaran Wu
  • Xinzhe Li
  • Liang Xu
  • Jiqin Lian
  • Fengtian He
Experimental Cell Research (2014) 328 (2): 379.
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
  • Eilin Austreid
  • Per Eystein Lonning
  • Hans Petter Eikesdal
Expert Opinion on Pharmacotherapy (2014) 15 (5): 681.
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
  • Feifei Li
  • Changqi Zhao
  • Lili Wang
International Journal of Cancer (2014) 134 (6): 1257.
Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives
  • TaeHun Kim
  • Gyochang Keum
  • Ae Nim Pae
Expert Opinion on Therapeutic Patents (2013) 23 (8): 919.
Hsp90 inhibitors in breast cancer: A systematic review
  • Flora Zagouri
  • Theodoros N. Sergentanis
  • Dimosthenis Chrysikos
  • Christos A. Papadimitriou
  • Meletios-Athanassios Dimopoulos
  • Theodora Psaltopoulou
The Breast (2013) 22 (5): 569.
Molecular targets and mechanisms of radiosensitization using DNA damage response pathways
  • David R Raleigh
  • Daphne A Haas-Kogan
Future Oncology (2013) 9 (2): 219.
Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening
  • JianMin Jia
  • XiaoLi Xu
  • Fang Liu
  • XiaoKe Guo
  • MingYe Zhang
  • MengChen Lu
  • LiLi Xu
  • JinLian Wei
  • Jia Zhu
  • ShengLie Zhang
  • ShengMiao Zhang
  • HaoPeng Sun
  • QiDong You
  • Freddie Salsbury
PLoS ONE (2013) 8 (4): e59315.
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies
  • Erin Schenk
  • Andrea E. Wahner Hendrickson
  • Donald Northfelt
  • David O. Toft
  • Matthew M. Ames
  • Michael Menefee
  • Daniel Satele
  • Rui Qin
  • Charles Erlichman
Investigational New Drugs (2013) 31 (5): 1251.
Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not
  • Maurizio Scaltriti
  • Shaheenah Dawood
  • Javier Cortes
Clinical Cancer Research (2012) 18 (17): 4508.
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
  • Komal Jhaveri
  • Tony Taldone
  • Shanu Modi
  • Gabriela Chiosis
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2012) 1823 (3): 742.
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins
  • Anne V. McNamara
  • Monica Barclay
  • Alastair J.M. Watson
  • John R. Jenkins
Biochemical Pharmacology (2012) 83 (3): 355.
HSP90 as a platform for the assembly of more effective cancer chemotherapy
  • Luke Whitesell
  • Nancy U. Lin
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2012) 1823 (3): 756.
Novel molecular targeted therapies for refractory thyroid cancer
  • Cesar A. Perez
  • Edgardo S. Santos
  • Belisario A. Arango
  • Luis E. Raez
  • Ezra E. W. Cohen
Head & Neck (2012) 34 (5): 736.
Monitoring the Induction of Heat Shock Factor 1/Heat Shock Protein 70 Expression following 17-Allylamino-Demethoxygeldanamycin Treatment by Positron Emission Tomography and Optical Reporter Gene Imaging
  • Mikhail Doubrovin
  • Jian T. Che
  • Inna Serganova
  • Ekaterina Moroz
  • David B. Solit
  • Lyudmila Ageyeva
  • Tatiana Kochetkova
  • Nagavarakishore Pillarsetti
  • Ronald Finn
  • Neal Rosen
  • Ronald G. Blasberg
Molecular Imaging (2012) 11 (1): 7290.2011.00028.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
  • Andrea E. Wahner Hendrickson
  • Ann L. Oberg
  • Gretchen Glaser
  • John K. Camoriano
  • Prema P. Peethambaram
  • Gerardo Colon-Otero
  • Charles Erlichman
  • S. Percy Ivy
  • Scott H. Kaufmann
  • Larry M. Karnitz
  • Paul Haluska
Gynecologic Oncology (2012) 124 (2): 210.
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
  • B H Kang
  • M Tavecchio
  • H L Goel
  • C-C Hsieh
  • D S Garlick
  • C M Raskett
  • J B Lian
  • G S Stein
  • L R Languino
  • D C Altieri
British Journal of Cancer (2011) 104 (4): 629.
Multi-drug delivery to tumor cells via micellar nanocarriers
  • Usha Katragadda
  • Quincy Teng
  • Bindhu Madhavi Rayaprolu
  • Thripthy Chandran
  • Chalet Tan
International Journal of Pharmaceutics (2011) 419 (1-2): 281.
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
  • Alessandro Allegra
  • Emanuela Sant’Antonio
  • Giuseppa Penna
  • Andrea Alonci
  • Arianna D’Angelo
  • Sabina Russo
  • Antonino Cannavò
  • Demetrio Gerace
  • Caterina Musolino
European Journal of Haematology (2011) 86 (2): 93.
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
  • Joleen Hubbard
  • Charles Erlichman
  • David O. Toft
  • Rui Qin
  • Bridget A. Stensgard
  • Sara Felten
  • Cynthia Ten Eyck
  • Gretchen Batzel
  • S. Percy Ivy
  • Paul Haluska
Investigational New Drugs (2011) 29 (3): 473.
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
  • Geoffrey I. Shapiro
  • Raoul Tibes
  • Michael S. Gordon
  • Bryan Y. Wong
  • Joseph Paul Eder
  • Mitesh J. Borad
  • David S. Mendelson
  • Nicholas J. Vogelzang
  • Bruno R. Bastos
  • Glen J. Weiss
  • Cristian Fernandez
  • William Sutherland
  • Hitoshi Sato
  • William E. Pierceall
  • David Weaver
  • Scott Slough
  • Ernesto Wasserman
  • Donald W. Kufe
  • Daniel Von Hoff
  • Takumi Kawabe
  • Sunil Sharma
Clinical Cancer Research (2011) 17 (10): 3431.
Tanespimycin as Antitumor Therapy
  • Meletios-Athanassios Dimopoulos
  • Constantine S. Mitsiades
  • Kenneth C. Anderson
  • Paul G. Richardson
Clinical Lymphoma Myeloma and Leukemia (2011) 11 (1): 17.
Heat Shock Proteins in Glioblastomas
  • Isaac Yang
  • Shanna Fang
  • Andrew T. Parsa
Neurosurgery Clinics of North America (2010) 21 (1): 111.
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells
  • Chun Hei Antonio Cheung
  • Huang-Hui Chen
  • Li-Ting Cheng
  • Kevin W. Lyu
  • Jagat R. Kanwar
  • Jang-Yang Chang
Molecular Cancer (2010) 9 (1)
Targeting the dynamic HSP90 complex in cancer
  • Jane Trepel
  • Mehdi Mollapour
  • Giuseppe Giaccone
  • Len Neckers
Nature Reviews Cancer (2010) 10 (8): 537.
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
  • Yun Dai
  • Steven Grant
Clinical Cancer Research (2010) 16 (2): 376.
Hsp90: A Drug Target?
  • Jeffrey M. Holzbeierlein
  • Andrew Windsperger
  • George Vielhauer
Current Oncology Reports (2010) 12 (2): 95.
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin
  • Ulka N. Vaishampayan
  • Angelika M. Burger
  • Edward A. Sausville
  • Lance K. Heilbrun
  • Jing Li
  • M. Naomi Horiba
  • Merrill J. Egorin
  • Percy Ivy
  • Simon Pacey
  • Patricia M. LoRusso
Clinical Cancer Research (2010) 16 (14): 3795.
Therapeutic Effects of Radiolabeled 17-Allylamino-17-Demethoxygeldanamycin on Human H460 Nonsmall-Cell Lung Carcinoma Xenografts in Mice
  • Jin Sun
  • Lu Liu
  • Xinyu Jiang
  • Daozhen Chen
  • Ying Huang
Cancer Biotherapy and Radiopharmaceuticals (2010) 25 (2): 155.
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
  • Bin Peng
  • Limin Xu
  • Fanfan Cao
  • Tingxuan Wei
  • Chunxin Yang
  • Georges Uzan
  • Denghai Zhang
Molecular Cancer (2010) 9 (1)
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
  • Dana Gancz
  • Zvi Fishelson
Molecular Immunology (2009) 46 (14): 2794.
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90
  • Charles Erlichman
Expert Opinion on Investigational Drugs (2009) 18 (6): 861.
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis
  • Wooin Lee
  • Jignesh H Patel
  • A Craig Lockhart
Expert Opinion on Investigational Drugs (2009) 18 (9): 1351.
New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential
  • Yanyan Li
  • Tao Zhang
  • Steven J. Schwartz
  • Duxin Sun
Drug Resistance Updates (2009) 12 (1-2): 17.
Identification of new Hsp90 inhibitors by structure-based virtual screening
  • Tae-Joon Hong
  • Hwangseo Park
  • Yun-Jung Kim
  • Jae-Hoon Jeong
  • Ji-Sook Hahn
Bioorganic & Medicinal Chemistry Letters (2009) 19 (16): 4839.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept